<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-red ">
                        28.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=28.000000000000004 class=" progress-red ">28.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-red ">
                        0.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=0.0 class=" progress-red ">0.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">28%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Focus on improving the Generator&#39;s handling of complex questions, as indicated by the overall low complex question score of 0.28. Additionally, address the significant knowledge base gaps in the &#34;Others&#34; and &#34;Over-the-Counter Drugs&#34; topics to ensure more comprehensive coverage across all topics.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"55ac481f-9623-422d-bfd9-5f59f28b99f1":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p2895","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p2897","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p2904","attributes":{"factors":["ACE Inhibitors and Hypertension Treatment","Antihypertensive Medications","NUCYNTA Medication Information","Others","Over-the-Counter Drugs","Tizanidine Hydrochloride"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p2905"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p2906"},"title":{"type":"object","name":"Title","id":"p2902","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2924","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2892","attributes":{"selected":{"type":"object","name":"Selection","id":"p2893","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2894"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAADAUkCqqqqqqqpAQCRJkiRJkjxAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFlA"},"shape":[6],"dtype":"float64","order":"little"}],["metadata_values",["ACE Inhibitors and Hypertension Treatment","Antihypertensive Medications","NUCYNTA Medication Information","Others","Over-the-Counter Drugs","Tizanidine Hydrochloride"]],["colors",["#84ca66","#fdbe6e","#fba55c","#a50026","#a50026","#006837"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2925","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2926"}}},"glyph":{"type":"object","name":"HBar","id":"p2921","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2922","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2923","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2933","attributes":{"data_source":{"id":"p2892"},"view":{"type":"object","name":"CDSView","id":"p2934","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2935"}}},"glyph":{"type":"object","name":"HBar","id":"p2930","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p2931","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p2932","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2943","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p2937","attributes":{"selected":{"type":"object","name":"Selection","id":"p2938","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2939"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p2944","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2945"}}},"glyph":{"type":"object","name":"Line","id":"p2940","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p2941","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p2942","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2903","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p2917","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p2912","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p2913"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p2914"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2915"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2907","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2908","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2909"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2910"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2911","attributes":{"axis":{"id":"p2907"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2916","attributes":{"dimension":1,"axis":{"id":"p2912"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p2936","attributes":{"location":28.000000000000004,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p2946","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2947","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p2943"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"55ac481f-9623-422d-bfd9-5f59f28b99f1","roots":{"p2895":"bfcfde47-d511-49be-a312-c2a42edc5a02"},"root_ids":["p2895"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="bfcfde47-d511-49be-a312-c2a42edc5a02" data-root-id="p2895" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"8438c7db-2a92-43d5-9245-6a3fba52789f":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p2826","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p2756","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p2707","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2716","attributes":{"start":4.772611427307129,"end":18.093423271179198}},"y_range":{"type":"object","name":"Range1d","id":"p2717","attributes":{"start":2.1853257417678833,"end":12.307798743247986}},"x_scale":{"type":"object","name":"LinearScale","id":"p2718"},"y_scale":{"type":"object","name":"LinearScale","id":"p2719"},"title":{"type":"object","name":"Title","id":"p2714","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2747","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2704","attributes":{"selected":{"type":"object","name":"Selection","id":"p2705","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2706"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"cdDzQHQz5UBBvBxB9mskQfSCGEHNkR5BgRYhQXjuKUFoFShBFuYiQS8ZH0EtuhdBsLoaQXwOHEEVLw9BEo0PQTtZEEErgShBwxgSQQtzKEF6dSFBOfwnQfTXKEGVHhlBx0kQQZcb/UArg/tA4NP5QNet+EBb4OhAhhSuQOKfrkDrTZNAi8yRQBj+oEAOkZlAQDCMQCPrlkDO2qJAPuV4QL77f0AHJ4pAetV3QNE1iEAujbNA24CTQI2Zo0Aba5RASZmjQAnIm0CR5Z5Ag3a2QF5HvUDV4cxAv2nCQMAPy0D4RrxAqGMOQc7tG0Gx3xJBA2kKQRNq20B9yOpAnRDhQPEs2EBZZt1AUdniQKOT40AO0fJAVyXLQD2RykCz1+9A9qXWQC2y8UD5k/1AEU7kQNF89EBkJPVAGBTnQBAWy0BwogVBOS7/QJY9+EBq6OdAbVP5QN6+/EDHBOJA5+feQC2b5UBhNc1AgzvSQEvo5UCRnL9A+zXJQOeI2ED7lu9AJNzaQJjx0UBcXMBA/ELNQI454kBtq+JAueS/QBLYvEAUmclAgmvzQMov1EABTtdAkxPPQOqN1kBIzM9A2pbAQBfYDUHzBAlBsmwHQdMsCkHP/uFA"},"shape":[117],"dtype":"float32","order":"little"}],["topic",["Pharmaceutical Products","Pharmaceutical Products","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","Others","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","Pharmaceutical Products","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Others","Pharmaceutical Products","Pharmaceutical Products","NUCYNTA Medication Information","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Hypertension Medication","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Tizanidine Pharmacology and Usage","Pharmaceutical Products","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],["content",["ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","K2resource co., ltd.\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:72191-0100\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSODIUM BICARBONATE\\n (UNII: 8MDF5V39QO) \\n(SODIUM CATION -\\nUNII:LYR4M0NH37)\\nSODIUM\\nBICARBONATE\\n36.2 g  in 100 mg\\nXYLITOL\\n (UNII: VCQ006KQ1E) \\n(XYLITOL - UNII:VCQ006KQ1E)\\nXYLITOL\\n5 g  in 100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMENTHOL\\n (UNII: L7T10EIP3A)\\n \\nProduct Characteristics\\nCo...","NUCYNTA - tapentadol hydrochloride tablet, film coated \\n \\nStat Rx USA\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use NUCYNTA\\u2122 safely and effectively. See full\\nprescribing information for NUCYNTA\\u2122.\\n \\nNUCYNTA\\u2122 (tapentadol) immediate-release oral tablets    C-II\\nInitial U.S. Approval: 2008\\nRECENT MAJOR CHANGES\\nWarnings and Precautions (\\n5.4\\n)\\nJune 2009\\nINDICATIONS AND USAGE\\nNUCYNTA\\u2122 is an opioid analgesic indicated for the relief o...","USE IN SPECIFIC POPULATIONS\\nLabor and delivery: \\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\nmothers have been taking NUCYNTA\\u2122, for respiratory depression. (\\n8.2\\n)\\nNursing mothers: should not breast-feed. (\\n8.3\\n)\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\n8.4\\n)\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\npatients with moder...","8.7 Hepatic Impairment\\n9 DRUG ABUSE AND DEPENDENCE\\n9.1 Controlled Substance\\n9.2 Abuse\\n9.3 Dependence\\n10 OVERDOSAGE\\n10.1 Human Experience\\n10.2 Management of Overdose\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n13 NON-CLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n13.2 Animal Toxicology and/or Pharmacology\\n14 CLINICAL STUDIES\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\n14.2 End-Stage Degenerative Joint Disea...","Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\nbeen studied and are not recommended.\\nNUCYNTA\\u2122 may be given with or without food \\n[see \\nClinical Pharmacology (12.3)\\n].\\n2.1 Renal Impairment\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\n[see \\nClinical\\nPharmacology (12.3)\\n]\\n.\\nNUCYNTA\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\nis not recommended.\\n2.2 Hepatic Im...","which may result in adverse cardiovascular events \\n[see \\nDrug Interactions (7.4)\\n]\\n.\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Respiratory Depression\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\nsignificantly decrease pulmonary ventilation.\\nNUCYNTA\\u2122 should be ...","5.5 Driving and Operating Machinery\\nPatients should be cautioned that NUCYNTA\\u2122 may impair the mental and/or physical abilities required\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\ncombination with alcohol or tranquilizers\\n [see \\nDrug Interactions (7.3)\\n]\\n.\\n5.6 Interactions with Alcohol and Drugs of Abuse\\nDue to its mu-opioid agonist activity,...","Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\nconsidered drug-related.\\nBased on data from nine Phase 2/3 studies that administered multiple...","*\\nInfections and infestations\\n  Nasopharyngitis\\n1\\n&lt;1\\n  Upper respiratory tract infection\\n1\\n&lt;1\\n  Urinary tract infection\\n1\\n&lt;1\\nMetabolism and nutrition disorders\\n  Decreased appetite\\n2\\n0\\nMusculoskeletal and connective tissue\\ndisorders\\n  Arthralgia\\n1\\n&lt;1\\nNervous system disorders\\n  Dizziness\\n24\\n8\\n  Somnolence\\n15\\n3\\n  Tremor\\n1\\n&lt;1\\n  Lethargy\\n1\\n&lt;1\\nPsychiatric disorders\\n  Insomnia\\n2\\n&lt;1\\n  Confusional state\\n1\\n0\\n  Abnormal dreams\\n1\\n&lt;1\\n  Anxiety\\n1\\n&lt;1\\nSkin and subcutaneous tissue disorders\\n  Pruritus\\n5\\n1\\n  Hyp...","Psychiatric disorders:\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\nabnormal\\nRenal and urinary disorders:\\n urinary hesitation, pollakiuria\\nRespiratory, thoracic and mediastinal disorders: \\noxygen saturation decreased, cough, dyspnea,\\nrespiratory depression\\nSkin and subcutaneous tissue disorders: \\nurticaria\\nVascular disorders:\\n blood pressure decreased\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\nNUCYNTA\\u2122,...","Pregnancy Category C.\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\nagonist properties.\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\nexhibit respiratory difficulties and withdrawal symptoms \\n[see \\nWarnings and Precautions (5.1)\\n]\\n. Use of\\nNUCYNTA\\u2122 in this population has not been characterized. As NUCYNTA\\u2122 h...","intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\nshould be taken to secure the airway.\\n11 DESCRIPTION\\nNUCYNTA\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\nThe chemical name is 3-[(1\\nR\\n,2\\nR\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\nmonohydrochloride. The structural formula is:\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\nH\\nNO\\u00b7HCl. The\\nn-octanol:water pa...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","Pharmacokinetic Drug Interactions\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\nconsidered clinically relevant and no change in dose is required.\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\nac...","14 CLINICAL STUDIES\\nThe efficacy and safety of NUCYNTA\\u2122 in the treatment of moderate to severe acute pain has been\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\u2122...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\nor greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus placebo.\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nNUCYNTA\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\nbiconvex-shaped.\\n50 mg tablets are yellow and debossed with \\"O-M\\" on one side and \\"50\\" on the other side, and are\\navailable in bottles of 100 (NDC 50458-820-04) a...","Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\u2122 \\n[see \\nUse in\\nSpecific Populations (8.3)\\n]\\n.\\n17.6 Monoamine Oxidase Inhibitors\\nPatients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine\\noxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\n17.7 Seizures\\nPatients should be informed that NU...","you get a new prescription. There may be new information. This Medication Guide does not take\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\ndoctor if you have any questions.\\nWhat is the most important information I should know about NUCYNTA\\u2122?\\nNUCYNTA\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\nUse NUCYNTA\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\u2122 if it has not been\\nprescribed for you.\\nYou sh...","Do not change the dose of NUCYNTA\\u2122 unless your doctor tells you to. \\nYour doctor may\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\u2122 more often\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\u2122.\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\u2122 to help lessen\\nwithdrawal symptoms.\\nNUCYNTA\\u2122 can be taken with or without food.\\nWhat should I avoid while taking NUCYNTA\\u2122?\\nDo not drive, operate machinery, ...","Store NUCYNTA\\u2122 at 59\\u00baF to 86\\u00baF (15\\u00baC to 30\\u00baC). Keep NUCYNTA\\u2122 tablets dry.\\nDispose of NUCYNTA\\u2122 tablets you no longer need.\\nKeep NUCYNTA\\u2122 in a safe place out of the reach of children.\\nGeneral information about NUCYNTA\\u2122\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\nuse NUCYNTA\\u2122 for a condition for which it was not prescribed. \\nDo not give NUCYNTA\\u2122 to other\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\u2122 could be harmful\\n...","NUCYNTA 100MG PACKAGE LABEL\\n       \\n   \\n   \\n   \\n   \\n   \\n   \\nNUCYNTA  \\ntapentadol hydrochloride tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN\\nPRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:16590-\\n863(NDC:50458-820)\\nRoute of Administration\\nORAL\\nDEA Schedule\\nCII","Active Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII: 15FIX9V2JP)\\n...","Stat Rx USA\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII:...","GRX DYNE - povidone iodine solution \\n \\nGeritrex Corp.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nGRx Dyne Solution\\nDrug Facts\\nActive Ingredient:                      Purpose\\nPovidone Iodine USP, 10% w/v  Antiseptic\\n(equivalent to 1% titratable Iodine)\\nUses\\nFirst aid antiseptic to help the risk of infection in \\nminor cuts, scra...","Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\nkeep out of reach of children. If swallowed get medical help \\nor contact a Poison Control Center right away.\\nEnter section text here\\nGRX DYNE  \\npovidone iodine solution\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:54162-269\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85...","Geritrex Corp.\\nCITRIC ACID MONOHYDRATE\\n (UNII: 2968PHW8QP)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM HYDROXIDE\\n (UNII: 55X04QC32I)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:54162-269-16\\n472 mL in 1 BOTTLE, PLASTIC\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOTC monograph not final\\npart333A\\n05/16/2012\\nLabeler - \\n...","LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\ntablets tablet \\n \\nCipla USA Inc.\\n----------\\nLisinopril and Hydrochlorothiazide Tablets, USP\\nRx Only\\nWARNING: FETAL TOXICITY\\nSee full prescribing information for complete boxed warning.\\nWhen pregnancy is detected, discontinue lisinopril and\\nhydrochlorothiazide tablets as soon as possible.\\nDrugs that act directly on the renin-angiotensin system can cause\\ninjury and death to the developing fetus. See \\nWarnings: Fetal Toxicity\\n.\\n...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\nadministration of the separate entities.\\nLisinopril\\nMechanism of Action\\n \\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...","state is prolonged. Older patients, on average, have (approximately doubled) higher\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\npatients (see \\nDOSAGE AND ADMINISTRATION\\n). In a multiple dose pharmacokinetic study\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\nhe...","accompanied by some loss of potassium and bicarbonate.\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\nabout 6 to 12 hours.\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...","the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\nsimilar risk (See \\nWARNINGS\\n).\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\nthan in nonblack patients (see \\nWARNIN...","Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\ninhibitor may be at increased risk for angioedema (see \\nPRECAUTIONS\\n).\\nIntestinal Angioedema:\\n Intestinal angioedema has been reported in patients treated\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\nC-1...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\nLisinopril and Hydrochlorothiazide\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\nMaternal or fetotoxic effects were not seen in mice with the com...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","therapy.\\nInformation for Patients\\nAngioedema:\\n Angioedema, including laryngeal edema may occur at any time during\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\nconsulted with the prescribing physician.\\nSymp...","DOSAGE AND ADMINISTRATION\\n)\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\nInhibitors (COX-2 Inhibitors):\\n \\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\nfunction, including possible acute renal failure. These effects are usually reversible.\\nMonitor ...","mTOR (mammalian target of rapamycin) inhibitors\\n \\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\n(see \\nWARNINGS\\n)\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\nrisk for angioedema. (see \\nWARNINGS\\n)\\nHydrochlorothiazide\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\nAlcohol, barbiturates, or nar...","in vitro\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\nchromosomal aberrations in an \\nin vitro\\n test in Chinese hamster ovary cells or in an \\nin\\nvivo\\n study in mouse bone marrow.\\nLisinopril\\n \\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\nmaximum daily human dose, based on body weight and body surface area,\\nrespectively). There was no ...","Nursing Mothers\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\nrats contains radioactivity following administration of \\nC lisinopril. In another study,\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\nwhether to discontinue nursing and/or disco...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","In rare cases, intestinal angioedema has been reported in post marketing experience.\\nHypotension:\\n In clinical trials, adverse effects relating to hypotension occurred as\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\nWARNINGS\\n).\\nCough:\\n See \\nPRECAUTIONS - Cough\\n.\\nClinical Laboratory Test Findings Serum Electrolytes:\\n (See \\nPRECAUTIONS\\n).\\nCreatinine, Blood Urea Nitrogen:\\n Minor reversible incre...","hallucinations; \\nRespiratory:\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\nSkin:\\n Urticaria, alopecia,\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\npsoriasis, rare cases of other severe skin reactions, includin...","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","possible, be discontinued for two to three days before beginning therapy with lisinopril\\nto reduce the likelihood of hypotension (See \\nWARNINGS\\n). If the patient\\u2019s blood pressure\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\nfor at least an additional hour (See \\nWARNINGS\\n and \\nPRECAUTIONS\\n...","Protect from excessive light and humidity.\\n*AN69 is a registered trademark of Hospal Ltd.\\nManufactured by:\\nInvaGen Pharmaceuticals, Inc.\\n(a subsidiary of Cipla Ltd.)\\nHauppauge, NY 11788\\nManufactured for:\\nCipla USA, Inc.\\n10 Independence Boulevard, Suite 300\\nWarren, NJ 07059\\nRevised: 10/2021\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\u2013 10 mg/12.5 mg\\nNDC 69097-968-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n10 mg/12.5 mg\\n100 Tablets\\nCipla\\nNDC 69097-969-07             ...","Cipla\\nNDC 69097-971-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n20 mg/25 mg\\n100 Tablets\\nCipla\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","lisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-969\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS D...","LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-971\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n25 mg\\nInactive Ingredients\\nI...","Cipla USA Inc.\\nLabeler - \\nCipla USA Inc. \\n(078719707)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen\\nPharmaceuticals, Inc\\n165104469\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\n69097-969, 69097-971)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen Pharmaceuticals, Inc\\n080334903\\npack(69097-968, 69097-969, 69097-971)\\n \\nRevised: 11/2021","ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\nphenylephrine hydrochloride tablet, coated \\n \\nMARC GLASSMAN, INC.\\n----------\\n1128B-MAR-2022-1005\\nDrug Facts\\nActive ingredients \\n(in each caplet)\\nPurpose\\nAcetaminophen 325 mg\\nPain reliever\\nChlorpheniramine maleate\\n2 mg\\nAntihistamine\\nPhenylephrine HCl 5 mg\\nNasal decongestant\\nUses\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\nallergies:\\nheadache\\nsinus congestion and pressure\\nnasal congestion\\nrunny nose...","If a skin reaction occurs, stop use and seek medical help right away.\\nDo not use\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\npharmacist.\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\ndr...","800-222-1222). Quick medical attention is critical for adults as well as for children even if\\nyou do not notice any signs or symptoms.\\nDirections\\ndo not take more than directed (see \\noverdose warning\\n)\\nadults and\\nchildren 12\\nyears and over\\ntake 2 caplets every 4 hours\\nswallow whole; do not crush,\\nchew, or dissolve\\ndo not take more than 10 caplets\\nin 24 hours\\nchildren under \\n12 years\\nask a doctor\\nOther information\\nstore between 20\\u00b0-25\\u00b0C (68\\u00b0-77\\u00b0F) in a dry place\\nretain carton for complete product...","ALLERGY MULTI SYMPTOM  \\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:68998-228\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCHLORPHENIRAMINE MALEATE\\n (UNII: V1Q0O9OJ9Z) \\n(CHLORPHENIRAMINE -\\nUNII:3U6IO1965U)\\nCHLORPHENIRAMINE\\nMALEATE\\n2 mg\\nPHENYLEPHRINE HYDROCHLORIDE\\n (UNII: 04JA59TNSJ) \\n(PHENYLEPHRINE -\\nUNII:1WS297W6MV)\\nPHENYLE...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\nhydrochlorothiazide tablet \\n \\nANI Pharmaceuticals, Inc.\\n----------\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\nWARNING: \\nFETAL TOXICITY\\n\\u2022\\n\\u2022\\nDESCRIPTION\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\nAT\\n) antagonist and a diuretic, hydrochlorothiazide.\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\np\\n-(\\no\\n-\\n1\\nH\\n...","Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\nand 12.5 mg or 25 mg of hydrochloroth...","The mechanism of the antihypertensive effect of thiazides is unknown.\\nPharmacokinetics\\nGeneral\\nCandesartan Cilexetil\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\nthe gastrointestinal tract to candesartan, a selective AT\\nsubtype angiotensin II receptor antagonist.\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\nIt undergoes minor hepatic\\nmetabolism by O-deethylation to an inactive metabolite. \\nThe elimination half...","Geriatric\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\u2265 65 years). \\nThe plasma\\nconcentration of candesartan was higher in the elderly (C\\n was approximately 50% higher, and AUC\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\nThe\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\nNo initia...","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","in myocardial infarction and cardiovascular mortality also have been seen regularly.\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\nhypertension can provide substantial benefit. \\nRelative risk reduction from blood pressure reduction is\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\nare at h...","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","considered if the intraocular pressure remains uncontrolled. \\nRisk factors for developing acute angle-\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\nHypersensitivity Reaction\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\nPRECAUTIONS\\nMetabolic Disturbances\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...","Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\npossible ac...","Cytotoxic products \\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\nCyclosporine \\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\ngout-type complications.\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\nhydrochlorothiazide. \\nThere was no evidence of c...","Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\nsubstituting for disordered renal function.\\nSafety and effectiveness in pediatric patients have not been established.\\nADVERSE REACTIONS\\nCandesartan Cilexetil and Hydrochlorothiazide\\nCandesartan cile...","melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\nfor white patients taking a cumulative dose of \\u226550,000 mg the risk increase was approximately 1\\nadditional SCC case for every 6,700 patients per year.\\nSkin:\\n \\nerythema multiforme including S...","Dose Titration by Clinical Effect: \\nA patient whose blood pressure is not controlled on 25 mg of\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\nA patient whose blood pressure is controlled on 25 mg of\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\nmg/12.5 mg and ser...","PRINCIPAL DISPLAY PANEL \\u2013 32 mg/12.5 mg\\nNDC 62559-661-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/12.5 mg\\nRx only\\n90 Tablets\\nPRINCIPAL DISPLAY PANEL \\u2013 32 mg/25 mg\\nNDC 62559-662-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/25 mg\\nRx only\\n90 Tablets","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:62559-660\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCANDESARTAN CILEXETIL\\n (UNII: R85M2X0D68) \\n(CANDESARTAN - UNII:S8Q36MD2XX)\\nCANDESARTAN\\nCILEXETIL\\n16 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n1...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","ANI Pharmaceuticals, Inc.\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-662-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nLabeler - \\nANI Pharmaceuticals, Inc. \\n(145588013)\\n \\nRevised: 5/2020","CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\n \\nCertus Medical, Inc.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\nDrug Facts Box OTC Active Ingredient Section\\nPovidone Iodine USP 10%\\nequivalent to 1% titratable iodine\\nDrug Facts Box OTC Purpose Section\\nAntiseptic\\nDrug...","Drug Facts Box OTC General Precautions Section\\nstore at room temperature 15\\n - 30\\n C (59\\n - 86\\n F)\\nDrug Facts Box OTC Inactive Ingredient Section\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\nCertus PVP-1 Prep Swabstick \\n210012 pouch\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\n0\\n0\\n0\\n0","CERTUS PVP-1 PREP SWABSTICK  \\npovidone-iodine swab\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:75990-4019\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85H0HZU99M) \\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\nPOVIDONE-IODINE\\n0.1 mL  in 1 mL\\nInactive Ingredients\\nIngredient Name\\nStrength","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\nmethoxycinnamate cream \\n \\nC&amp;BCOSMETIC Co.,Ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nDrug Facts\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\nWater, Glycerin, Butylene Glycol, Etc\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\nk...","ABALONE CRYSTALDOUBLE EX CC  \\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:60611-0008\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength","C&amp;BCOSMETIC Co.,Ltd.\\nNIACINAMIDE\\n (UNII: 25X51I8RD4) \\n(NIACINAMIDE - UNII:25X51I8RD4)\\nNIACINAMIDE\\n2 g  in 100 mL\\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP) \\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\nTITANIUM DIOXIDE\\n4.694 g  in 100 mL\\nADENOSINE\\n (UNII: K72T3FS567) \\n(ADENOSINE - UNII:K72T3FS567)\\nADENOSINE\\n0.04 g  in 100 mL\\nOCTINOXATE\\n (UNII: 4Y5P7MUD51) \\n(OCTINOXATE - UNII:4Y5P7MUD51)\\nOCTINOXATE\\n7 g  in 100 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C...","TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\n \\nAdvagen Pharma Limited\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use TIZANIDINE\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\n \\nInitial U.S. Approval: 1996\\nINDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...","Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\nfour-fold ( \\n8.5\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION.\\nRevised: 9/2020\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosing Information\\n2.2 Dosing in Patients with Renal Impairment\\n2.3 Dosing in Patients with Hepatic Impairment\\n2.4 Drug Discontinuation\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Hypo...","12.1 Mechanism of Action\\n12.3 Pharmacokinetics\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\n1 INDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\ntreatment with tizanid...","been studied.\\n2.2 Dosing in Patients with Renal Impairment\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\ndoses are required, individual doses rather than dosing frequency should be increased\\n[see Warnings and Precautions ( \\n5.7\\n)] \\n.\\n2.3 Dosing in Patients with Hepatic Impairment\\nT...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Clinical Pharmacology ( \\n12.3\\n)]\\n5.6 Hypersensitivity Reactions\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\nand symptoms occur. \\n[see Contraindications ( \\n4\\n)]\\n5.7 Increased Risk of Adverse Reactions in Patients...","264 patients received tizanidine and 261 patients received placebo. Across the three\\nstudies patient ages ranged from 15\\u201369 years and 51.4 percent were women. The\\nmedian dose during the plateau phase ranged from 20\\u201328 mg/day.\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\nclinical studies involving 264 patients with spasticity were dry mouth,\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\nThree-quarters of the patients rated t...","multiple sclerosis (Study 1) \\n[see Clinical Studies ( \\n14\\n)] \\n, the patients were specifically\\nasked if they had experienced any of the four most common adverse reactions: dry\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\nthese reactions is summarized in \\nTable 2\\n. Other events were, in general, reported at a\\nrate of 2% or less.\\nTable 2: Single Dose, Placebo-Controlled Study -...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","12.3\\n)]\\n7.7 \\u03b1 \\n-adrenergic agonists\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\nbe used with other \\u03b1 \\n-adrenergic agonists. \\n[see Warnings and Precautions ( \\n5.1\\n)]\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nPregnancy Category C\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...","8.6 Impaired Renal Function\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\nmore than 50%. In these patients, during titration, the individual doses should be\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\nshould be increased. These patients sho...","manifestations of tizanidine overdose were consistent with its known pharmacology. In\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\nmost often bradycardia and hypotension. Respiratory depression is another common\\nfeature of tizanidine overdose.\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\nmonitoring of cardiovascular and respiratory systems shou...","12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\nreduce facilitation of spinal motor neurons.\\n12.3 Pharmacokinetics\\nAbsorption and Distribution\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\n...","Metabolism and Excretion\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\u2013\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\nactive; their half-lives range from 20 to 40 hours.\\nFollowing single and multiple oral dosing of \\nC-tizanidine, an average of 60%...","this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\nused with caution in renally impaired patients \\n[see Warnings and Precautions ( \\n5.7\\n) and\\nUse in Specific Populations ( \\n8.6\\n)] \\n.\\nGender Effects\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\npharmacokinetic...","13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\nCarcinogenesis\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\nbasis.\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\nwhich is 2.5 times the MRHD on a mg/m \\nbasis. There was no increase in tumors in\\neither species.\\nMutagenesis\\nTizanidine was negative in \\nin vitro\\n(bacterial r...","tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\nincluding hypotension were more common and more severe than in the 8 mg group.\\nThere were no differences in the number of spasms occurring in each group.\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\nMeasured by ...","from baseline as measured by the Ashworth scale.\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\nAfter Dosing as Measured by the Ashworth Scale \\u00b1 95% Confidence Interval\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\nBaseline)\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...","17 PATIENT COUNSELING INFORMATION\\nSerious Drug Interactions\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\npharmacists when they start or stop taking any medication because of the risks\\nassociated with interaction between tizanidine and other medicines.\\nTizanidine Dosing\\nTell patients ...","PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15","TIZANIDINE HYDROCHLORIDE  \\ntizanidine hydrochloride capsule\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:72888-001\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of\\nStrength\\nStrength\\nTIZANIDINE HYDROCHLORIDE\\n (UNII: B53E3NMY5C) \\n(TIZANIDINE -\\nUNII:6AI06C00GW)\\nTIZANIDINE\\n2 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE...","AMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\nScore\\nno score\\nShape\\nCAPSULE\\nSize\\n11mm\\nFlavor\\nImprint Code\\nUpArrowhead;043\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:72888-001-\\n15\\n150 \\nin 1 BOTTLE; Type 0: Not a Combination\\nProduct\\n05/27/2020\\nMarketing Information\\nMarketing\\nCategory\\nAppl...","GELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPROPYL ALCOHOL\\n (UNII: ND2M416302)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nALCOHOL\\n (UNII: 3K9958V90M)\\n \\nBUTYL ALCOHOL\\n (UNII: 8PJ61P6TS3)\\n \\nAMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque)...","Inactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE, UNSPECIFIED\\n (UNII: 3NXW29V3WO)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nSTEARIC ACID\\n (UNII: 4ELV7Z65AP)\\n \\nGELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPRO...","Advagen Pharma Limited\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nRubicon Research\\nPrivate Limited\\n677604197\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\n \\nRevised: 7/2024","ATHLETES FOOT- butenafine hydrochloride cream \\n \\nRite Aid Corporation\\n----------\\nAthlete&#x27;s Foot Cream\\nDrug Facts\\nActive ingredient\\nButenafine hydrochloride 1%\\nPurpose\\nAntifungal\\nUses\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\nfoot is unknown.\\ncures most jock itch and ringworm\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\nWarnings\\nFor external use only\\nDo not use\\non nails or scalp\\nin or near the mouth or the eyes\\nfor vag...","1 week twice a day or 4 weeks once a day\\nfor jock itch and ringworm:\\napply once a day to affected skin for 2 weeks or as\\ndirected by a doctor.\\nwash hands after each use\\nchildren under 12 years: ask a doctor\\nOther information\\ndo not use if seal on tube is broken or not visible\\nstore between 20\\u00ba to 25\\u00ba C (68\\u00ba to 77\\u00ba F)\\nInactive ingredients\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...","RITE \\nAID \\n \\nPHARMACY\\nclinically proven to cure \\nmost athlete&#x27;s foot between the toes\\nfoot care \\nbutenafine\\nhydrochloride cream 1%\\nantifungal\\nNET WT 0.42 OZ (12 g)\\n\\u00ae","ATHLETES FOOT  \\nbutenafine hydrochloride cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11822-2100\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nBUTENAFINE HYDROCHLORIDE\\n (UNII: R8XA2029ZI) \\n(BUTENAFINE -\\nUNII:91Y494NL0X)\\nBUTENAFINE\\nHYDROCHLORIDE\\n10 mg\\n in 1 g\\nInactive Ingredients\\nIngredient Name\\nStrength\\nBENZYL ALCOHOL\\n (UNII: LKG8494WBH)\\n \\nCETYL ALCOHOL\\n (UNII: 936JST6JCN)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n...","Rite Aid Corporation\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nANDA\\nANDA205181\\n11/17/2017\\nLabeler - \\nRite Aid Corporation \\n(014578892)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nTaro Pharmaceuticals Inc.\\n206263295\\nmanufacture(11822-2100)\\n \\nRevised: 7/2024"]],["color",{"type":"ndarray","array":["#ffbb78","#ffbb78","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#999","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ffbb78","#999","#ffbb78","#ffbb78","#ffbb78","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#999","#ffbb78","#ffbb78","#ffbb78","#999","#ffbb78","#ffbb78","#ff7f0e","#ffbb78","#ffbb78","#ffbb78","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#ffbb78","#999","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78"],"shape":[117],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2748","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2749"}}},"glyph":{"type":"object","name":"Scatter","id":"p2744","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2745","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2746","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2715","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p2730","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p2731"},{"type":"object","name":"WheelZoomTool","id":"p2732","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2733","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2734","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2739"},{"type":"object","name":"SaveTool","id":"p2740"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2725","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2726","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2727"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2728"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2720","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2721","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2722"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2723"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2724","attributes":{"axis":{"id":"p2720"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2729","attributes":{"dimension":1,"axis":{"id":"p2725"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2750","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2751","attributes":{"label":{"type":"value","value":"Hypertension Medication"},"renderers":[{"id":"p2747"}],"index":30}},{"type":"object","name":"LegendItem","id":"p2752","attributes":{"label":{"type":"value","value":"NUCYNTA Medication Information"},"renderers":[{"id":"p2747"}],"index":2}},{"type":"object","name":"LegendItem","id":"p2753","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p2747"}],"index":16}},{"type":"object","name":"LegendItem","id":"p2754","attributes":{"label":{"type":"value","value":"Pharmaceutical Products"},"renderers":[{"id":"p2747"}],"index":0}},{"type":"object","name":"LegendItem","id":"p2755","attributes":{"label":{"type":"value","value":"Tizanidine Pharmacology and Usage"},"renderers":[{"id":"p2747"}],"index":87}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p2825","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p2761","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p2770","attributes":{"start":4.772611427307129,"end":18.093423271179198}},"y_range":{"type":"object","name":"Range1d","id":"p2771","attributes":{"start":2.1853257417678833,"end":12.307798743247986}},"x_scale":{"type":"object","name":"LinearScale","id":"p2772"},"y_scale":{"type":"object","name":"LinearScale","id":"p2773"},"title":{"type":"object","name":"Title","id":"p2768","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p2800","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2757","attributes":{"selected":{"type":"object","name":"Selection","id":"p2758","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2759"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"olU1QbHgHUGYpTFBhYnDQMEESUGs3RBBNKG2QHsHGUFWRQxBOllBQfCdM0GNvztBP/Y7QRDxEEG7Jg9BerH5QADTyUChthpBl2EXQRWQKEF/EsJAaALvQD7/EEG8oNRA4jspQQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"9NcoQeDT+UAVLw9BUdniQIEWIUFb4OhAjZmjQDku/0AX2A1BgzvSQAtzKEHDGBJBzZEeQcov1EBx0PNAZCT1QD7leECx3xJBE2rbQJcb/UA9kcpA4p+uQPMECUF61XdAAU7XQA=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["NUCYNTA Medication Information","Over-the-Counter Drugs","NUCYNTA Medication Information","Antihypertensive Medications","NUCYNTA Medication Information","Over-the-Counter Drugs","ACE Inhibitors and Hypertension Treatment","Over-the-Counter Drugs","Over-the-Counter Drugs","Tizanidine Hydrochloride","NUCYNTA Medication Information","NUCYNTA Medication Information","NUCYNTA Medication Information","Over-the-Counter Drugs","Over-the-Counter Drugs","Antihypertensive Medications","ACE Inhibitors and Hypertension Treatment","Over-the-Counter Drugs","Over-the-Counter Drugs","NUCYNTA Medication Information","Antihypertensive Medications","ACE Inhibitors and Hypertension Treatment","Over-the-Counter Drugs","ACE Inhibitors and Hypertension Treatment","Others"]],["correctness",[true,false,true,true,false,false,true,false,false,true,false,false,false,false,false,false,true,false,false,false,false,false,false,true,false]],["questions",["While on NUCYNTA\\u2122, what specific activities should be strictly avoided, especially considering the risk of drowsiness and other serious side effects, and what are the potential consequences if these activities are not avoided?","Could you specify the primary active ingredient found in GRx Dyne Solution, along with its intended function, while also mentioning any restrictions on its use?","Considering the pharmacological details provided, what is the proposed mechanism by which Tapentadol achieves its analgesic effects, and how does this relate to its potency compared to morphine?","In hypertensive patients, what specific impact does candesartan cilexetil have on serum potassium levels, particularly when administered at a dose of 32 mg, and are there any notable changes in metabolic functions such as cholesterol or glucose levels?","When administering NUCYNTA\\u2122 to patients with respiratory conditions such as asthma or COPD, what specific precautions should be taken to prevent respiratory depression, and under what circumstances should alternative analgesics be considered?","Considering the marketing information provided, including the application number or monograph citation, what is the specific start date for the marketing of Geritrex Corp.&#x27;s product identified by NDC:54162-269-16?","Considering the adverse effects of lisinopril plus hydrochlorothiazide, which ones are most frequently responsible for patients deciding to stop the medication, and how do these compare to the incidence of similar effects in a placebo group?","Could you list the inactive ingredients found in Certus PVP-1 Prep Swabstick, ensuring to include any that might be present in minimal quantities or have uncommon chemical names?","Under the condition that you are looking for an antifungal treatment specifically for athlete&#x27;s foot, what is the primary active component in the Athlete&#x27;s Foot Cream produced by Rite Aid Corporation?","In patients on high doses of Tizanidine hydrochloride capsules for extended periods or those also using narcotics, what is the advised method for discontinuing the medication to avoid adverse effects like withdrawal symptoms, and what specific dose reduction steps should be followed?","Considering the storage conditions and safety instructions, what are the different strengths and packaging formats available for NUCYNTA\\u2122 tablets?","In the study focused on end-stage degenerative joint disease, what was the main method used to assess the effectiveness of NUCYNTA\\u2122, considering the constraints of a 10-day treatment period and the requirement for a 3-day mean pain score of \\u22655 on an 11-point scale?","Considering the potential risks, could you elaborate on the specific medical conditions or treatments that would make the use of NUCYNTA\\u2122 inadvisable, especially in relation to respiratory issues, gastrointestinal problems, or recent use of certain antidepressants?","Could you specify the National Drug Code (NDC) assigned to the bottle containing 150 capsules with a dosage of 6 mg, ensuring it is distinct from other dosages listed in the document?","Considering that ADEA GARGLE is not FDA-approved, could you detail its primary applications, specifically focusing on its oral care benefits and any precautions one should take when using it?","Could you list the active ingredients and their respective strengths found in the pink, oval candesartan cilexetil and hydrochlorothiazide tablet, specifically the one with the imprint code ACD, ensuring you distinguish it from other similar tablets based on the color and imprint code?","When administering lisinopril to patients with impaired renal function, especially those with severe congestive heart failure or unilateral/bilateral renal artery stenosis, what specific precautions and monitoring steps should be prioritized to prevent potential complications such as oliguria or acute renal failure?","Considering the provided guidelines, what is the advised dosage for adults and children aged 12 and above when using the Allergy Multi-Symptom medication, and what are the specific instructions regarding the maximum number of caplets and method of ingestion?","Considering the details provided by MARC GLASSMAN, INC., what is the specific flavor of the product, and how does it relate to its other characteristics such as color and shape?","Considering the specific characteristics of the yellow round tablets, such as their color and shape, what is the precise dosage strength of tapentadol they contain?","When administering Candesartan Cilexetil in conjunction with NSAIDs, particularly in elderly or volume-depleted patients, what specific renal function parameters should be monitored, and how frequently should these checks occur to prevent potential acute renal failure?","Considering the inactive ingredients and the clinical efficacy in different patient groups, what are the specific tablet combinations available for lisinopril and hydrochlorothiazide?","Considering the treatment guidelines for jock itch and ringworm, how often should the medication be applied to the affected area, and are there any specific instructions for children under 12 years old or if the tube&#x27;s seal is compromised?","When lisinopril is administered alongside lithium, what specific parameters should be closely monitored, especially considering potential drug interactions and the risk of lithium toxicity?","In the Tizanidine Hydrochloride capsules meant for human prescription, what is the primary active ingredient and its exact dosage strength, ensuring to exclude any inactive components?"]],["agent_answer",["While on NUCYNTA\\u2122, activities that should be strictly avoided due to the risk of drowsiness and other serious side effects include:\\n\\n1. Driving or operating heavy machinery - NUCYNTA\\u2122 can cause drowsiness, dizziness, and impaired cognition, which can significantly impair a person&#x27;s ability to safely operate a vehicle or machinery. Engaging in these activities while under the influence of NUCYNTA\\u2122 can lead to accidents, injuries, or even fatalities.\\n\\n2. Drinking alcohol - Alcohol can enhance the side effects of NUCYNTA\\u2122, including drowsiness and dizziness. Combining NUCYNTA\\u2122 with alcohol can increase the risk of overdose, respiratory depression, and other serious complications.\\n\\n3. Engaging in activities that require alertness and coordination - Activities such as hiking, rock climbing, or participating in sports that require quick reflexes and coordination should be avoided while taking NUCYNTA\\u2122. Impaired alertness and coordination can increase the risk of accidents and injuries.\\n\\nIf these activities are not avoided while taking NUCYNTA\\u2122, the potential consequences can be severe, including:\\n\\n- Accidents or injuries that can result in hospitalization or long-term disability.\\n- Increased risk of overdose or other adverse reactions due to impaired cognition and reflexes.\\n- Legal consequences such as DUI charges if caught driving under the influence of NUCYNTA\\u2122 and alcohol.\\n- Strained relationships with loved ones or coworkers due to impaired judgment and behavior.\\n\\nIt is crucial to follow the healthcare provider&#x27;s instructions while taking NUCYNTA\\u2122 and to avoid activities that can jeopardize safety and well-being. If unsure about specific activities, it is essential to consult with a healthcare provider before engaging in them while on NUCYNTA\\u2122.","The primary active ingredient in GRx Dyne Solution is propylene glycol. Its intended function is to act as a humectant, which helps to attract and retain moisture in the skin. \\n\\nThere are no specific restrictions mentioned for the use of propylene glycol in GRx Dyne Solution. However, it is always recommended to perform a patch test before using any new skincare product to check for any potential allergies or sensitivities. If irritation occurs, discontinue use immediately.","Tapentadol achieves its analgesic effects by acting as both a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. This dual mechanism of action allows Tapentadol to not only activate opioid receptors in the central nervous system but also inhibit the reuptake of norepinephrine, which can enhance the descending inhibitory pathways involved in pain modulation.\\n\\nIn terms of potency compared to morphine, Tapentadol is considered to be equipotent to morphine when administered orally. However, due to its unique mechanism of action involving both opioid receptor activation and norepinephrine reuptake inhibition, Tapentadol may offer improved analgesic efficacy and a reduced risk of side effects commonly associated with traditional opioids, such as respiratory depression and constipation. This dual mechanism also helps to mitigate the development of tolerance and dependence, making Tapentadol a potentially safer option for long-term pain management.","In hypertensive patients, candesartan cilexetil at a dose of 32 mg is not typically associated with significant changes in serum potassium levels. However, it is important to monitor potassium levels closely, especially in patients with underlying renal dysfunction or those taking other medications that may affect potassium levels.\\n\\nAs for changes in metabolic functions, candesartan cilexetil is not known to have a significant impact on cholesterol or glucose levels. Some studies have suggested that it may have a neutral effect on these parameters or even lead to slight improvements in lipid profiles.\\n\\nIt is always important to closely monitor all metabolic parameters in hypertensive patients, especially when starting a new medication like candesartan cilexetil, and to individualize treatment based on the patient&#x27;s specific metabolic profile and overall health.","When administering NUCYNTA\\u2122 to patients with respiratory conditions such as asthma or COPD, specific precautions should be taken to prevent respiratory depression by closely monitoring the patient&#x27;s respiratory status, especially when starting or increasing the dosage of the medication. In addition, patients with pre-existing respiratory conditions should be prescribed the lowest effective dose of NUCYNTA\\u2122 and should be closely monitored for signs of respiratory depression, such as slow or shallow breathing.\\n\\nAlternative analgesics should be considered in patients with respiratory conditions if they experience significant respiratory depression, as this can be life-threatening. In such cases, alternative analgesics that are less likely to cause respiratory depression, such as non-opioid analgesics or opioid analgesics with a lower risk of respiratory depression, may be considered as an alternative treatment option. It is important for healthcare providers to assess the risks and benefits of NUCYNTA\\u2122 and alternative analgesics on a case-by-case basis to determine the most appropriate treatment for each individual patient with respiratory conditions.","Based on the marketing information provided, the specific start date for the marketing of Geritrex Corp.&#x27;s product identified by NDC:54162-269-16 is not explicitly mentioned. To determine the specific start date for the marketing of this product, further research or accessing the company&#x27;s specific marketing documents or records may be necessary.","The most frequent adverse effects of lisinopril plus hydrochlorothiazide that lead patients to stop the medication are often related to intolerable side effects such as dizziness, lightheadedness, fatigue, erectile dysfunction, and persistent cough. These side effects can significantly impact a patient&#x27;s quality of life and may outweigh the benefits of the medication.\\n\\nIn comparison to a placebo group, the incidence of these adverse effects is typically higher in the lisinopril plus hydrochlorothiazide group. This is because both lisinopril and hydrochlorothiazide can cause specific adverse effects, and when combined, the risk of experiencing these side effects is increased. Additionally, the placebo group does not receive the active ingredients in the medication, so they are less likely to experience these adverse effects.","The inactive ingredients in Certus PVP-1 Prep Swabstick include purified water, isopropyl alcohol, citric acid, and sodium hydroxide. There may also be additional inactive ingredients present in minimal quantities or with uncommon chemical names that are not disclosed on the product label.","The primary active component in the Athlete&#x27;s Foot Cream produced by Rite Aid Corporation is typically clotrimazole.","The advised method for discontinuing Tizanidine hydrochloride capsules in patients on high doses for extended periods or those also using narcotics is to gradually taper off the medication under the supervision of a healthcare provider. This is to avoid withdrawal symptoms and other potential adverse effects.\\n\\nWhen reducing the dose of Tizanidine hydrochloride capsules, a specific dose reduction schedule should be followed. The recommended steps for dose reduction may include:\\n\\n1. Decreasing the dose gradually over a period of time, typically by reducing the dose by 2-4 mg every 3-4 days.\\n2. Monitoring for any signs of withdrawal symptoms or adverse effects during the dose reduction process.\\n3. Adjusting the tapering schedule as needed based on the individual patient&#x27;s response and tolerance to the medication.\\n4. Providing support and counseling for the patient to help manage any potential withdrawal symptoms or difficulties during the tapering process.\\n\\nIt is important for patients to follow the guidance of their healthcare provider when discontinuing Tizanidine hydrochloride capsules to ensure a safe and effective tapering process.","NUCYNTA\\u2122 tablets are available in different strengths of 50 mg, 75 mg, and 100 mg. They are available in packaging formats such as blister packs and bottles. It is important to store NUCYNTA\\u2122 tablets at room temperature (between 20-25\\u00b0C or 68-77\\u00b0F) and away from moisture and heat. Additionally, they should be kept out of reach of children and pets.","The main method used to assess the effectiveness of NUCYNTA\\u2122 in the study focused on end-stage degenerative joint disease was evaluating the change in mean pain score on an 11-point scale over the 10-day treatment period. The study required participants to have a mean pain score of \\u22655 on the 11-point scale for at least 3 days to be included in the analysis. This method allowed researchers to assess how NUCYNTA\\u2122 impacted pain levels in individuals with end-stage degenerative joint disease within a relatively short timeframe.","NUCYNTA\\u2122 is a prescription opioid medication that carries certain risks, especially when used in individuals with specific medical conditions or those undergoing certain treatments. In relation to respiratory issues, NUCYNTA\\u2122 should be used with caution in patients with asthma or other respiratory conditions that could be exacerbated by the respiratory depressant effects of opioids. \\n\\nAdditionally, individuals with gastrointestinal problems such as inflammatory bowel disease, gastrointestinal bleeding, or a history of diverticulitis may be at an increased risk of developing gastrointestinal side effects while taking NUCYNTA\\u2122, such as constipation or gastrointestinal bleeding. Patients with these conditions should be closely monitored while taking the medication.\\n\\nFurthermore, the use of certain antidepressants, specifically MAO inhibitors, within the past 14 days is contraindicated with NUCYNTA\\u2122 due to the potential for serotonin syndrome, a serious and potentially life-threatening condition. Additionally, the concurrent use of NUCYNTA\\u2122 with other serotonergic medications, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), should be carefully considered and monitored for the development of serotonin syndrome.\\n\\nIn summary, individuals with respiratory issues, gastrointestinal problems, or recent use of certain antidepressants should use NUCYNTA\\u2122 with caution and under close medical supervision to minimize the risks associated with these specific medical conditions or treatments.","Unfortunately, without knowing the specific details or context of the document you are referring to, I am unable to provide the National Drug Code (NDC) for the bottle containing 150 capsules with a dosage of 6 mg. The NDC is a unique identifier for drugs and medical products, and the specific code assigned to a particular product can vary depending on the manufacturer and specific details of the product. If you can provide more information or context, I may be able to assist you further in finding the specific NDC for the product you are inquiring about.","ADEA GARGLE is a herbal oral care product that is not FDA-approved. Its primary applications include promoting oral hygiene, reducing bad breath, soothing sore throats, and providing relief from minor mouth and throat irritations. \\n\\nSome of the oral care benefits of ADEA GARGLE include its ability to effectively kill bacteria and viruses in the mouth, preventing cavities and gum disease, reducing inflammation in the gums, and freshening breath.\\n\\nWhen using ADEA GARGLE, it is important to take some precautions. It is recommended to dilute the gargle with water before use, as it may be too strong to use directly. It is also important to avoid swallowing the gargle and to not use it more frequently than recommended by the manufacturer. If any adverse reactions occur, such as irritation or allergic reactions, it is important to discontinue use and consult a healthcare professional. Additionally, it is advised to consult with a healthcare provider before using ADEA GARGLE if you are pregnant, breastfeeding, or have any underlying medical conditions.","The pink, oval candesartan cilexetil and hydrochlorothiazide tablet with the imprint code ACD contains the following active ingredients and strengths:\\n\\n1. Candesartan cilexetil - 16 mg\\n2. Hydrochlorothiazide - 12.5 mg\\n\\nThis tablet is distinguishable by its pink color and imprint code ACD.","When administering lisinopril to patients with impaired renal function, especially those with severe congestive heart failure or unilateral/bilateral renal artery stenosis, the following specific precautions and monitoring steps should be prioritized to prevent potential complications such as oliguria or acute renal failure:\\n\\n1. Baseline renal function assessment: Before starting lisinopril therapy, it is crucial to assess the patient&#x27;s baseline renal function through serum creatinine and estimated glomerular filtration rate (eGFR) measurements. This will help identify patients at higher risk for renal complications.\\n\\n2. Renal function monitoring: Regular monitoring of renal function, including serum creatinine and eGFR measurements, should be performed throughout the course of lisinopril therapy. This monitoring should be more frequent in patients with pre-existing renal impairment or risk factors for renal dysfunction.\\n\\n3. Fluid status monitoring: Patients with impaired renal function are at a higher risk of developing volume depletion and electrolyte imbalances. Monitoring fluid status, including daily weight measurements and assessing for signs of fluid overload or dehydration, is essential to prevent complications such as oliguria or acute renal failure.\\n\\n4. Blood pressure monitoring: Lisinopril is primarily used for managing hypertension, but it can also cause hypotension, especially in patients with impaired renal function. Regular blood pressure monitoring is necessary to ensure adequate blood pressure control without causing hypotension-related renal complications.\\n\\n5. Electrolyte monitoring: Lisinopril can affect electrolyte balance, particularly potassium levels. Monitoring serum potassium levels is crucial, especially in patients with renal impairment or those taking other medications that can alter potassium levels.\\n\\n6. Avoiding concurrent nephrotoxic medications: Patients with impaired renal function should avoid taking other nephrotoxic medications concurrently with lisinopril. Careful consideration should be given to the potential interactions and cumulative effects on renal function.\\n\\n7. Dose adjustment: In patients with impaired renal function, dose adjustments may be necessary based on their renal function status. Lower starting doses and slower titration schedules may be recommended to minimize the risk of renal complications.\\n\\n8. Patient education: Patients should be educated about the importance of medication adherence, fluid intake management, and monitoring for signs of renal impairment. They should also be advised to seek medical attention if they experience symptoms suggestive of renal dysfunction, such as decreased urine output or swelling.\\n\\nBy prioritizing these precautions and monitoring steps, healthcare providers can help prevent potential complications such as oliguria or acute renal failure in patients with impaired renal function receiving lisinopril therapy.","The advised dosage for adults and children aged 12 and above when using the Allergy Multi-Symptom medication is one caplet every 4 to 6 hours as needed. The maximum number of caplets that can be taken in a 24-hour period should not exceed 6 caplets. The caplets should be taken with a full glass of water and should not be crushed or chewed. It is important to follow the instructions on the label and consult a healthcare provider if experiencing any side effects or concerns.","The specific flavor of the product provided by MARC GLASSMAN, INC. is lemon. This flavor relates to its other characteristics such as color and shape by being reflected in a bright yellow color and a round, citrus fruit-like shape. The lemon flavor, color, and shape work together to create a cohesive and appealing product experience for consumers.","Without additional information or context about the specific yellow round tablets being referenced, it is not possible to provide a precise dosage strength of tapentadol contained in them. The color and shape of a tablet can sometimes provide clues about its manufacturer or characteristics, but the exact dosage strength would need to be confirmed by referring to the packaging, consulting a healthcare professional, or checking the manufacturer&#x27;s website for specific product information.","When administering Candesartan Cilexetil in conjunction with NSAIDs, particularly in elderly or volume-depleted patients, specific renal function parameters that should be monitored include serum creatinine levels and estimated glomerular filtration rate (eGFR). These checks should occur at baseline before starting treatment, and then regularly throughout therapy, such as every 1-2 weeks initially and then at least monthly thereafter.\\n\\nMonitoring these renal function parameters is crucial to prevent potential acute renal failure, as both Candesartan Cilexetil and NSAIDs can affect renal function and combining them may increase the risk of renal impairment. By monitoring renal function regularly, healthcare providers can detect any changes early and adjust treatment as needed to prevent complications.","Some specific tablet combinations available for lisinopril and hydrochlorothiazide include:\\n\\n1. Lisinopril 20 mg/Hydrochlorothiazide 12.5 mg\\n2. Lisinopril 20 mg/Hydrochlorothiazide 25 mg\\n3. Lisinopril 40 mg/Hydrochlorothiazide 12.5 mg\\n4. Lisinopril 40 mg/Hydrochlorothiazide 25 mg\\n\\nThese combinations are commonly used in the treatment of hypertension and can be prescribed by healthcare providers based on the individual patient&#x27;s needs and response to treatment. It is important to note that the specific tablet combinations may vary based on the manufacturer and formulation.","For jock itch and ringworm, the medication should typically be applied to the affected area 1-2 times daily, as directed by a healthcare professional or as stated on the medication packaging. For children under 12 years old, it is important to follow the dosage instructions provided by a healthcare professional or the medication packaging, as children may require different dosages based on their age and weight.\\n\\nIf the tube&#x27;s seal is compromised, it is important to not use the medication and to contact the pharmacist or healthcare provider for further instructions. Using a medication with a compromised seal can lead to contamination and potential harm to the skin.\\n\\nIt is always important to carefully read and follow the instructions provided with any medication, and to consult a healthcare professional if there are any questions or concerns about the treatment guidelines.","When lisinopril is administered alongside lithium, specific parameters that should be closely monitored include lithium serum levels, renal function, and adverse effects such as dizziness, confusion, and muscle weakness. This is important because lisinopril can increase lithium levels in the body, leading to a higher risk of lithium toxicity. Patients should also be monitored for symptoms of lithium toxicity such as diarrhea, vomiting, tremors, and difficulty walking. Close monitoring and dose adjustments may be necessary to avoid potential drug interactions and adverse effects.","The primary active ingredient in Tizanidine Hydrochloride capsules is tizanidine hydrochloride. The exact dosage strength of tizanidine hydrochloride in these capsules may vary depending on the prescription, but common strengths include 2 mg and 4 mg. Inactive components such as fillers and binders are not included in this response as per the instruction."]],["reference_answer",["Do not drive, operate machinery, or participate in any other possibly dangerous activities until you know how you react to this medicine. NUCYNTA\\u2122 can make you sleepy. You should not drink alcohol while using NUCYNTA\\u2122. Alcohol increases your chance of having dangerous side effects.","The active ingredient in GRx Dyne Solution is Povidone Iodine USP, 10% w/v (equivalent to 1% titratable Iodine), and its purpose is as an antiseptic.","Tapentadol is a centrally-acting synthetic analgesic, and its analgesic efficacy is thought to be due to mu-opioid agonist activity and the inhibition of norepinephrine reuptake.","In spite of the effect of candesartan cilexetil on aldosterone secretion, very little effect on serum potassium was observed.","NUCYNTA\\u2122 should be administered with caution to patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve such as asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA\\u2122 may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA\\u2122 should be employed only under careful medical supervision at the lowest effective dose in such patients.","The marketing start date is 05/16/2012.","The most common adverse effects leading to discontinuation are dizziness, cough, fatigue, and muscle cramps.","The inactive ingredients in Certus PVP-1 Prep Swabstick are disodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, and water.","Butenafine hydrochloride 1%","If therapy needs to be discontinued, particularly in patients who have been receiving high doses (20 mg to 36 mg daily) for long periods (9 weeks or more) or who may be on concomitant treatment with narcotics, the dose should be decreased slowly (2 mg to 4 mg per day) to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia.","NUCYNTA\\u2122 tablets are available in 50 mg, 75 mg, and 100 mg strengths. The 50 mg tablets are yellow, the 75 mg tablets are yellow-orange, and the 100 mg tablets are orange. All tablets are debossed with &#x27;O-M&#x27; on one side and the respective strength on the other side. They are available in bottles of 100 and hospital unit dose blister packs of 10.","Efficacy was evaluated by comparing the sum of pain intensity difference (SPID) versus placebo over the first five days of treatment.","NUCYNTA\\u2122 is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment, acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment, paralytic ileus, and in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days.","The NDC code for the 6 mg 150 capsules bottle is 72888-003-15.","ADEA GARGLE is used for oral care, including tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and tartar formation, plaque removal, and oral cleansing.","The active ingredients in the pink tablet with imprint code ACD are candesartan cilexetil at a strength of 32 mg and hydrochlorothiazide at a strength of 25 mg.","In patients with impaired renal function, changes in renal function may be anticipated, especially in those with severe congestive heart failure or renal artery stenosis. Increases in blood urea nitrogen and serum creatinine may occur, which are usually reversible upon discontinuation of lisinopril and/or diuretic therapy. Renal function should be monitored during the first few weeks of therapy, and dosage reduction of lisinopril and/or discontinuation of the diuretic may be required.","Adults and children 12 years and over should take 2 caplets every 4 hours, and not take more than 10 caplets in 24 hours.","MINT","The strength of tapentadol in the yellow round tablets is 50 mg.","Monitor renal function periodically in patients receiving candesartan and NSAID therapy.","Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.","Apply once a day to affected skin for 2 weeks or as directed by a doctor.","It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium.","The active ingredient in Tizanidine Hydrochloride capsules is Tizanidine, with a strength of 2 mg."]],["id",[22,27,14,66,6,29,46,81,114,92,19,18,5,108,0,77,39,59,61,25,70,31,115,42,109]],["content",["Do not change the dose of NUCYNTA\\u2122 unless your doctor tells you to. \\nYour doctor may\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\u2122 more often\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\u2122.\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\u2122 to help lessen\\nwithdrawal symptoms.\\nNUCYNTA\\u2122 can be taken with or without food.\\nWhat should I avoid while taking NUCYNTA\\u2122?\\nDo not drive, operate machinery, ...","GRX DYNE - povidone iodine solution \\n \\nGeritrex Corp.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nGRx Dyne Solution\\nDrug Facts\\nActive Ingredient:                      Purpose\\nPovidone Iodine USP, 10% w/v  Antiseptic\\n(equivalent to 1% titratable Iodine)\\nUses\\nFirst aid antiseptic to help the risk of infection in \\nminor cuts, scra...","intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\nshould be taken to secure the airway.\\n11 DESCRIPTION\\nNUCYNTA\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\nThe chemical name is 3-[(1\\nR\\n,2\\nR\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\nmonohydrochloride. The structural formula is:\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\nH\\nNO\\u00b7HCl. The\\nn-octanol:water pa...","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","which may result in adverse cardiovascular events \\n[see \\nDrug Interactions (7.4)\\n]\\n.\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Respiratory Depression\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\nsignificantly decrease pulmonary ventilation.\\nNUCYNTA\\u2122 should be ...","Geritrex Corp.\\nCITRIC ACID MONOHYDRATE\\n (UNII: 2968PHW8QP)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM HYDROXIDE\\n (UNII: 55X04QC32I)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:54162-269-16\\n472 mL in 1 BOTTLE, PLASTIC\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOTC monograph not final\\npart333A\\n05/16/2012\\nLabeler - \\n...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","Drug Facts Box OTC General Precautions Section\\nstore at room temperature 15\\n - 30\\n C (59\\n - 86\\n F)\\nDrug Facts Box OTC Inactive Ingredient Section\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\nCertus PVP-1 Prep Swabstick \\n210012 pouch\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\n0\\n0\\n0\\n0","ATHLETES FOOT- butenafine hydrochloride cream \\n \\nRite Aid Corporation\\n----------\\nAthlete&#x27;s Foot Cream\\nDrug Facts\\nActive ingredient\\nButenafine hydrochloride 1%\\nPurpose\\nAntifungal\\nUses\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\nfoot is unknown.\\ncures most jock itch and ringworm\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\nWarnings\\nFor external use only\\nDo not use\\non nails or scalp\\nin or near the mouth or the eyes\\nfor vag...","been studied.\\n2.2 Dosing in Patients with Renal Impairment\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\ndoses are required, individual doses rather than dosing frequency should be increased\\n[see Warnings and Precautions ( \\n5.7\\n)] \\n.\\n2.3 Dosing in Patients with Hepatic Impairment\\nT...","The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\nor greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus placebo.\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nNUCYNTA\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\nbiconvex-shaped.\\n50 mg tablets are yellow and debossed with \\"O-M\\" on one side and \\"50\\" on the other side, and are\\navailable in bottles of 100 (NDC 50458-820-04) a...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\nbeen studied and are not recommended.\\nNUCYNTA\\u2122 may be given with or without food \\n[see \\nClinical Pharmacology (12.3)\\n].\\n2.1 Renal Impairment\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\n[see \\nClinical\\nPharmacology (12.3)\\n]\\n.\\nNUCYNTA\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\nis not recommended.\\n2.2 Hepatic Im...","PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15","ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","800-222-1222). Quick medical attention is critical for adults as well as for children even if\\nyou do not notice any signs or symptoms.\\nDirections\\ndo not take more than directed (see \\noverdose warning\\n)\\nadults and\\nchildren 12\\nyears and over\\ntake 2 caplets every 4 hours\\nswallow whole; do not crush,\\nchew, or dissolve\\ndo not take more than 10 caplets\\nin 24 hours\\nchildren under \\n12 years\\nask a doctor\\nOther information\\nstore between 20\\u00b0-25\\u00b0C (68\\u00b0-77\\u00b0F) in a dry place\\nretain carton for complete product...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","Active Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII: 15FIX9V2JP)\\n...","Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\npossible ac...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","1 week twice a day or 4 weeks once a day\\nfor jock itch and ringworm:\\napply once a day to affected skin for 2 weeks or as\\ndirected by a doctor.\\nwash hands after each use\\nchildren under 12 years: ask a doctor\\nOther information\\ndo not use if seal on tube is broken or not visible\\nstore between 20\\u00ba to 25\\u00ba C (68\\u00ba to 77\\u00ba F)\\nInactive ingredients\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...","DOSAGE AND ADMINISTRATION\\n)\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\nInhibitors (COX-2 Inhibitors):\\n \\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\nfunction, including possible acute renal failure. These effects are usually reversible.\\nMonitor ...","TIZANIDINE HYDROCHLORIDE  \\ntizanidine hydrochloride capsule\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:72888-001\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of\\nStrength\\nStrength\\nTIZANIDINE HYDROCHLORIDE\\n (UNII: B53E3NMY5C) \\n(TIZANIDINE -\\nUNII:6AI06C00GW)\\nTIZANIDINE\\n2 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE..."]],["color",["#0a980a","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e"]]]}}},"view":{"type":"object","name":"CDSView","id":"p2801","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2802"}}},"glyph":{"type":"object","name":"Scatter","id":"p2797","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2798","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2799","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p2815","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p2806","attributes":{"selected":{"type":"object","name":"Selection","id":"p2807","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2808"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p2816","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p2817"}}},"glyph":{"type":"object","name":"Scatter","id":"p2812","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p2813","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p2814","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p2769","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p2784"},{"type":"object","name":"WheelZoomTool","id":"p2785","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p2786","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p2787","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p2792"},{"type":"object","name":"SaveTool","id":"p2793"},{"type":"object","name":"HoverTool","id":"p2760","attributes":{"renderers":[{"id":"p2800"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p2779","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2780","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2781"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2782"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p2774","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p2775","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p2776"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p2777"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p2778","attributes":{"axis":{"id":"p2774"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p2783","attributes":{"dimension":1,"axis":{"id":"p2779"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p2803","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p2804","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p2800"}],"index":1}},{"type":"object","name":"LegendItem","id":"p2805","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p2800"}],"index":0}}]}},{"type":"object","name":"LabelSet","id":"p2821","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p2818","attributes":{"selected":{"type":"object","name":"Selection","id":"p2819","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p2820"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"QSVFQRyBykBVjjdBow4UQRXo1UA="},"shape":[5],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"zEHVQLdc5UBNJB5BJMDtQDFal0A="},"shape":[5],"dtype":"float32","order":"little"}],["topic",["Tizanidine Pharmacology and Usage","Hypertension Medication","NUCYNTA Medication Information","Pharmaceutical Products","Hypertension Medication"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"8438c7db-2a92-43d5-9245-6a3fba52789f","roots":{"p2826":"df966b66-4cba-4948-836f-230cecaa4dbb"},"root_ids":["p2826"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="df966b66-4cba-4948-836f-230cecaa4dbb" data-root-id="p2826" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
